ANAB ANAPTYSBIO, INC Insider Trading

Director Schmid sells 20,645 shares across 3 transactions for $1,158,451.43; reduces stake 39.5% to 31,622 shares at blended $56.11

John P. Schmid, a Director at Anaptysbio, conducted 3 separate sales totaling 20,645 shares for $1,158,451.43, reducing his holdings by 39.5% from 52,267 to 31,622 shares. The sales occurred at prices ($55.71, $56.70, $57.40) near the current price of $56.73, while the stock trades 15.7% below its 52-week high of $67.29. The company shows strong recent fundamentals with revenue of $76,320,000 and net income of $15,113,000 in the latest quarter, though it was unprofitable over the full prior fiscal year. Notably, Schmid's cross-ticker track record shows 7 prior buys with a 71.43% 90-day win rate and average 90-day returns of +30.2%, though this sale represents a departure from that historical buying pattern.

ANAB CEO Faga Daniel sells 17,679 shares (17.7K) for $1,089,198.74 across 10 transactions; stock rose 11%+ in 30 days post-January sales.

Faga Daniel, President and CEO of ANAB, executed 10 separate sales totaling 17,679 shares for $1,089,198.74 on 2026-03-27, reducing his holdings from 513,644 to 495,965 shares (a -3.4% reduction). The sales occurred at prices ranging from $56.61 to $65.99, with a blended average of $61.61, while the current stock price stands at $57.40. Notably, his two most recent prior sales at ANAB on 2026-01-08 and 2026-01-05 both posted strong 30-day returns (+11.2% and +11.8% respectively), suggesting those earlier sales were poorly-timed entries into a rising market. At the same-ticker level, his 90-day well-timed rate is 0 of 2 measurable outcomes, indicating his prior sales at this stock have not preceded declines. The company recently reported revenue of $76,320,000.00 in the latest quarter with net income of $15,113,000.00, but was unprofitable on a full-year basis, and carries a P/E of 34.79 against a market cap of $1,650,149,837.00. The stock is currently -14.7% from its 52-week high of $67.29.

Chief Legal Officer sells 10,000 ANAB shares at $54.00; stock now $53.08, near 52-week high of $55.25

LOUMEAU ERIC J sold 10,000 shares (43.8% reduction from 22,835 to 12,835 shares held) at $54.00 on 2026-02-11, for $540,000.00 total value. The stock is currently trading at $53.08, only -3.9% from its 52-week high of $55.25, and has appreciated 57.0% over the past 90 days and 5.6% over 30 days. His prior five sales at this ticker have been mixed: three showed negative 30-day returns (-8.5%, -2.8%, -0.7%) and two showed positive returns (+3.7%, +2.4%), with no measurable 90-day outcomes yet available for any of these December 2025 transactions. The company posted strong recent fundamentals (Q4 revenue $76.3M, net income $15.1M, 432.0% annual revenue growth), though it was unprofitable over its most recent full fiscal year. The sale reduces the insider's stake meaningfully but at a price near recent highs in a strong uptrend.

ANAB CEO Faga Daniel sold 14,281 shares at $44.71 on 2026-01-08 (value: $638,503.51); retains 479,344 shares. Stock -12.3% from 52-week high; prior ANAB sales posted +12.0% and +0.5% 90-day returns.

CEO Faga Daniel sold 14,281 shares at $44.71, reducing holdings by 2.9% while retaining a substantial 479,344 share position. This represents a second discretionary sale within 3 days (a prior sale on 2026-01-05 was also reported). The stock has declined 12.3% from its 52-week high of $50.91 but remains positive on a 90-day basis (+42.4%), suggesting recent strength before this transaction. Notably, his two prior measurable sales at ANAB (2024-03-25 and 2024-03-22) were both poorly timed by the 90-day benchmark, with the stock rising +12.0% and +0.5% post-sale; his cross-ticker track record shows a 0.00% well-timed rate across 3 prior sells. The company posted strong recent fundamentals—$76.3M quarterly revenue with +432.0% annual growth and $15.1M net income—though it was unprofitable over its most recent full fiscal year, creating mixed signals about underlying sustainability.

CEO Daniel Faga sold 15,309 shares of ANAB at $43.26 for $662,267.34; holdings now 458,139 shares post-transaction.

Faga, as President and CEO, sold 15,309 shares on 2026-01-05, reducing his holdings by 3.2% to 458,139 shares while retaining substantial position. The sale occurred at $43.26, which was near the stock's 52-week high of $50.91 (within 15% of peak); at current price of $43.91, the executed price was slightly below market. Reviewing his prior trades at ANAB, both prior sells (2024-03-25 and 2024-03-22) were followed by positive 90-day returns (+12.0% and +0.5%), meaning neither sale preceded a decline. His cross-ticker track record shows 0 of 2 prior sells were well-timed, with an average 90-day return of +6.2% after sells. The fundamental backdrop is mixed: company posted revenue of $76,320,000 and net income of $15,113,000 in the latest quarter, alongside annual revenue growth of +432.0%, though it was unprofitable over its most recent full fiscal year. This sale represents a standard diversification move by a substantial shareholder without clear timing differentiation relative to his historical pattern.

ANAB Chief Legal Officer sells 10,000 shares at $51.00; stock up 126.0% in 90 days post-transaction completion pattern of 4 sales in 4 trading days

Eric J. Loumeau, Chief Legal Officer, sold 10,000 shares at $51.00 on 2025-12-22, reducing his holdings from 18,947 to 8,947 shares (52.8% reduction). This sale occurred as part of a concentrated pattern: the same insider sold on 2025-12-18, 2025-12-17, and twice on 2025-12-16, indicating four separate dispositions within a single trading week. The stock has appreciated significantly since the December transaction dates, with a 126.0% 90-day change and 30-day change of +26.3%, currently trading near its 52-week high of $50.33. While the company shows strong recent fundamentals—$76.3M in latest quarterly revenue, $15.1M net income, and +432.0% annual revenue growth—the rapid, consecutive nature of these insider sales across multiple trading days warrants investor attention to understand whether these transactions reflect a prearranged schedule, available liquidity needs, or other material factors.

Chief Legal Officer Eric Loumeau sold 22,641 shares for $1,027,425.25, reducing holdings by 71.7% across 4 transactions (12/16–12/18)

Eric Loumeau, Chief Legal Officer of AnaptysBio, executed 4 separate sales totaling 22,641 shares for $1,027,425.25 between December 16 and 18, 2025, at blended average price $45.38, reducing his post-transaction holdings to 8,947 shares from 31,588 shares (a 71.7% reduction). The transaction occurred as the stock near its 52-week high of $47.53 and after a 28.4% 30-day and 128.1% 90-day price surge. While the company shows strong recent results—$76.3M quarterly revenue, +432.0% annual growth, $15.1M net income in latest quarter—it was unprofitable on a full-year basis, indicating recent-quarter profitability may be a near-term inflection rather than sustained performance. The magnitude and timing of this sale, divesting over 70% of holdings at a share price within 0.1% of the 52-week peak, warrants attention to whether this reflects executive confidence in current valuation or other considerations.

CFO Dennis Mulroy sells 15,725 shares at $44.85 avg, reducing stake by 62.6%; stock up 28.4% in 30 days

Dennis Mulroy, Chief Financial Officer of AnaptysBio, executed 2 separate sales on 2025-12-16 totaling 15,725 shares (15.7K shares) for $705,332.78 ($705.3K), reducing his holdings from 25,126 shares (25.1K shares) to 9,401 shares (9.4K shares), a 62.6% reduction. The sales occurred at a blended average price of $44.85, near the current price of $47.53, which marks the 52-week high. This substantial liquidation follows a notable 30-day run of +28.4% and a 90-day surge of +128.1%, positioning the sale near the stock's peak valuation of the past year. While the company achieved strong fundamentals this quarter (Revenue $76,320,000.00 and Net income $15,113,000.00 with annual revenue growth of +432.0%), the full-year fiscal results were negative. The magnitude and timing of the CFO's exit warrants investor attention alongside monitoring of near-term operational performance.

EcoR1 Capital, LLC (Director) purchases 85,098 shares of ANAB for $1.1M at $12.92 blended average, as stock down 66.9% from 52-week high.

EcoR1 Capital purchased 85,098 shares across three separate transactions totaling $1,099,642.42, increasing holdings from 7.79M to 7.88M shares (+1.1%). The purchases occurred at $12.92 blended average as the stock traded at $13.36 current price, down 66.9% from its 52-week high of $40.33 and -39.3% over the prior 30 days. However, the insider's cross-ticker track record shows mixed timing: 8 prior open-market buys averaged -28.8% return over 90 days with a 0% win rate, while a prior August 2024 purchase at this same ticker showed -41.1% 90-day performance. ANAB itself remains unprofitable with $-32.9M net income on $30.0M quarterly revenue, though full-year revenue grew 66.8%, leaving fundamental recovery uncertain against recent shareholder losses.

EcoR1 Capital (10% owner) bought 273,972 shares of ANAB at $36.50 for $9,999,978.00

EcoR1 Capital, a 10% shareholder, purchased 273,972 shares at $36.50, bringing total holdings to 7,794,996 shares. The transaction occurred near the top of the 52-week range ($37.23), with the stock currently trading at $34.00 and down 8.7% from its high. Critically, EcoR1's cross-ticker track record shows 1 prior buy with a negative average 90d return of -16.5% and a 0.00% win rate, providing little confidence in the firm's market timing ability. The company itself is unprofitable with a $-46.7M net loss in the latest quarter despite strong 66.8% annual revenue growth, creating fundamental uncertainty that outweighs the signal from a large shareholder accumulation.